Three antidepressants worked better than fluoxetine, the drug sold for years as Prozac, at helping people with depression get better and stay well, according to a new antidepressant study. The research, published Nov. 10 in The Lancet Psychiatry, compared 20 antidepressants to see how well they eased symptoms and kept them from returning. The team drew on 115 earlier clinical trials involving more than 30,000 people.
The three drugs that stood out were escitalopram, sold as Lexapro; duloxetine, sold as Cymbalta; and agomelatine. All three performed better over the long term than fluoxetine in the antidepressant study, which used fluoxetine as the main comparison drug. Escitalopram came out ahead by the widest margin, with patients on the drug having 62 percent higher odds of staying well than those on fluoxetine.
Agomelatine ranked next, with 57 percent higher odds of a lasting response, and duloxetine followed at 40 percent higher odds. The figures come from the antidepressant study's network meta-analysis, a method that threads together direct and indirect comparisons between treatments. The main analysis drew on 35 head-to-head continuation trials, which enrolled patients who had already responded to treatment and tracked whether they stayed well.
What the antidepressant study compared
The antidepressant study defined long-term use as six months or more. The research team was led by Radboud University Medical Center in the Netherlands. Fluoxetine served as the reference point because it was the first drug in its class and has been around the longest. The team looked at two questions at once: how well each drug eased depression symptoms, and how well it kept those symptoms from coming back.
Escitalopram belongs to a common group of antidepressants called selective serotonin reuptake inhibitors, or SSRIs, which doctors often recommend as a first option. Among the SSRIs in the analysis, escitalopram appeared to work best at helping patients stay well over time. Duloxetine belongs to a different group, the SNRIs, and doctors prescribe it less often as a first choice.
Paul van Haaren, a researcher at Radboud who worked on the study, said the three drugs have different benefits and drawbacks. He said escitalopram is already widely used, agomelatine works well but carries a risk of liver failure, and duloxetine is less well known and is prescribed less often as a first-line treatment. Agomelatine is not approved for use in the United States.
Antidepressant study limits and cautions
The antidepressant study comes with limits that matter. Rather than enrolling a new group of patients and following them over time, the researchers combined results from 115 earlier trials. More than half of the 35 head-to-head continuation trials in the main analysis were judged to have a high risk of bias. Data beyond one year were scarce, and the team could not break out results by gender or ethnicity.
Eric Ruhe, a professor of difficult-to-treat depression at Radboud, said the findings could eventually shape how doctors choose antidepressants. He stressed that the results do not mean everyone with depression should take escitalopram. As a prescriber, he said, you weigh the balance between a drug's benefits and its side effects, and that balance differs from person to person.
Dr. Carole Lieberman, a psychiatrist in Beverly Hills, California, who was not involved in the research, urged caution in reading the results. She said the best way to treat depression is not always with antidepressants alone, and talk therapy can play an important role. Some patients benefit from using medication along with therapy, she said.
What patients should do
Eli Lilly told Fox News Digital that it stopped making Prozac in 2024. The company said fluoxetine remains available in many generic medicines approved by the Food and Drug Administration, and it noted that neither the antidepressant study nor the university's news release referred to Prozac or any Lilly product by name.
The researchers stressed that the results describe group averages and cannot predict which antidepressant will work best for a particular person. People with questions about their antidepressants should speak with their doctor before making any changes to their medication, according to the university's news release. If a medicine works and is tolerated, the antidepressant study gives no reason to change it.

